Literature DB >> 6938036

Prognostic significance of nuclear DNA levels in prostatic carcinoma.

A Zetterberg, P L Esposti.   

Abstract

Cytological smears prepared from fine needle aspiration biopsies of prostatic carcinoma were subjected to cytophotometric DNA analysis. A method was developed by which old May-Grünwald-Giemsa (MGG) stained smear preparations could be used for quantitative cytophotometric DNA determinations after the removal of the MGG stain and restaining specifically for DNA according to a modified Feulgen reaction. Up to 15 years old MGG-stained smears from 43 patients diagnosed as having prostatic carcinomas were so processed and submitted to cytophotometric analysis. The 43 patients were selected on the basis of the clinical response to hormone therapy. Patient group I (21 patients) showed a good response with survival without clinical evidence of cancer for at least five years. Patient group II (22 patients) showed a poor response with death from cancer within three years. Most of the carcinomas belonging to patient group I, were characterized by a diploid or a combined diploid-tetraploid DNA distribution pattern, while in carcinomas from patient group II, most of the cancer cells generally contained abnormally increased DNA amounts. In this second group some of the tumours exhibited clearly aneuploid modal distribution patterns with DNA values ranging from the hypotriploid level to the hypertetraploid level, while in other tumours a large intercellular variability in DNA content was the characteristic feature.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6938036

Source DB:  PubMed          Journal:  Scand J Urol Nephrol Suppl        ISSN: 0300-8886


  10 in total

1.  Statistical evaluation of the prognostic value of nuclear DNA content in papillary, follicular, and medullary thyroid tumors.

Authors:  M Bäckdahl; J Carstensen; G Auer; E Tallroth
Journal:  World J Surg       Date:  1986-12       Impact factor: 3.352

2.  Nuclear DNA patterns and survival in metastasizing ileal carcinoids.

Authors:  A P Nobin; K Erhardt; G Auer; S Falkmer; H Mårtensson
Journal:  World J Surg       Date:  1987-06       Impact factor: 3.352

3.  Prognostic value of nuclear DNA content in papillary thyroid carcinoma.

Authors:  K Cohn; M Bäckdahl; G Forsslund; G Auer; G Lundell; T Löwhagen; E Tallroth; J S Willems; A Zetterberg; P O Granberg
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

4.  Prognostic value of nuclear DNA content in medullary thyroid carcinoma.

Authors:  M Bäckdahl; E Tallroth; G Auer; G Forsslund; P O Granberg; G Lundell; T Löwhagen
Journal:  World J Surg       Date:  1985-12       Impact factor: 3.352

Review 5.  Clinical and biological significance of aneuploidy in human tumours.

Authors:  M L Friedlander; D W Hedley; I W Taylor
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

6.  Cytochemical changes in the nucleus during tumour development.

Authors:  T Caspersson; G Auer; A Fallenius; J Kudynowski
Journal:  Histochem J       Date:  1983-04

7.  Follicular tumors of the thyroid gland: diagnosis, clinical aspects and nuclear DNA analysis.

Authors:  J Zedenius; G Auer; M Bäckdahl; U Falkmer; L Grimelius; G Lundell; G Wallin
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

Review 8.  Aneuploidy as a promoter and suppressor of malignant growth.

Authors:  Anand Vasudevan; Klaske M Schukken; Erin L Sausville; Vishruth Girish; Oluwadamilare A Adebambo; Jason M Sheltzer
Journal:  Nat Rev Cancer       Date:  2021-01-11       Impact factor: 69.800

9.  Histopathological grading and DNA ploidy as prognostic markers in metastatic prostatic cancer.

Authors:  T Jørgensen; K Yogesan; F Skjørten; A Berner; K J Tveter; H E Danielsen
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

10.  Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer.

Authors:  L Li; K Mu; G Zhou; L Lan; G Auer; A Zetterberg
Journal:  Br J Cancer       Date:  2008-08-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.